My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 81

    1.

    Levodopa.

    Yahr MD.

    Ann Intern Med. 1975 Nov;83(5):677-82. Review.PMID: 128308 [PubMed - indexed for MEDLINE]Related articles

    2.

    Levodopa alone and in combination with a peripheral decarboxylase inhibitor benserazide (Madopar) in the treatment of Parkinson's disease: A controlled clinical trial.

    Rinne UK, Birket-Smith E, Dupont E, Hansen E, Hyyppä M, Marttila R, Mikkelsen B, Pakkenberg H, Presthus J.

    J Neurol. 1975 Dec 2;211(1):1-9.PMID: 56427 [PubMed - indexed for MEDLINE]Related articles

    3.

    Six-year results of treatment with levodopa plus benzerazide in Parkinson's disease.

    Barbeau A, Roy M.

    Neurology. 1976 May;26(5):399-404.PMID: 944392 [PubMed - indexed for MEDLINE]Related articles

    4.

    Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom.

    Lees AJ.

    BMJ. 1995 Dec 16;311(7020):1602-7.PMID: 8555803 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    The clinical efficacy of oral levodopa methyl ester solution in reversing afternoon "off" periods in Parkinson's disease.

    Steiger MJ, Stocchi F, Carta A, Ruggieri S, Agnoli A, Quinn NP, Marsden CD.

    Clin Neuropharmacol. 1991 Jun;14(3):241-4.PMID: 2070364 [PubMed - indexed for MEDLINE]Related articles

    6.

    Levodopa with benserazide or carbidopa in Parkinson disease.

    Rinne UK, Mölsä P.

    Neurology. 1979 Dec;29(12):1584-9.PMID: 574221 [PubMed - indexed for MEDLINE]Related articles

    7.

    Long-term treatment of Parkinson's disease with L-Dopa and Dopa-decarboxylase inhibitor: therapeutic results and side effects.

    Battistin L, Meneghetti G, Rigotti S, Saia A.

    Acta Neurol Scand. 1978 Feb;57(2):186-92.PMID: 347868 [PubMed - indexed for MEDLINE]Related articles

    8.

    Improved control of brittle Parkinsonism by separate administration of levodopa and benserazide.

    McLellan DL, Dean BC.

    Br Med J (Clin Res Ed). 1982 Apr 3;284(6321):1001-2.PMID: 6802383 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Study of deterioration in long-term treatment of parkinsonism with L-dopa plus decarboxylase inhibitor.

    Ludin HP, Bass-Verrey F.

    J Neural Transm. 1976;38(3-4):249-58.PMID: 956811 [PubMed - indexed for MEDLINE]Related articles

    10.

    Long-term responses of Parkinson's disease to levodopa therapy.

    Rinne UK, Sonninen V, Siirtola T, Marttila R.

    J Neural Transm Suppl. 1980;(16):149-56.PMID: 6776234 [PubMed - indexed for MEDLINE]Related articles

    11.

    [The combined treatment of Parkinson's disease with L-dopa plus decarboxylase inhibitors (carbidopa, benserazide) (author's transl)]

    Podiwinsky F, Mentasti M, Riederer P, Birkmayer W.

    Wien Klin Wochenschr. 1979 May 11;91(10):332-7. German. PMID: 452602 [PubMed - indexed for MEDLINE]Related articles

    12.

    Parkinson's disease treated with Sinemet or Madopar. A controlled multicenter trial.

    Pakkenberg H, Birket-Smith E, Dupont E, Hansen E, Mikkelsen B, Presthus J, Rautakorpi I, Riman E, Rinne UK.

    Acta Neurol Scand. 1976 May;53(5):376-85.PMID: 1266576 [PubMed - indexed for MEDLINE]Related articles

    13.

    [Combined treatment of the early stages of Parkinson's syndrome with bromocriptine and levodopa. The results of a multicenter study]

    Fischer PA, Przuntek H, Majer M, Welzel D.

    Dtsch Med Wochenschr. 1984 Aug 24;109(34):1279-83. German. PMID: 6381019 [PubMed - indexed for MEDLINE]Related articles

    14.

    Editorial: Long-term assessment of levodopa therapy in Parkinson's disease.

    Barbeau A.

    Can Med Assoc J. 1975 Jun 21;112(12):1379-80. No abstract available. PMID: 1139474 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Levodopa in the treatment of Parkinson's disease.

    Koller WC.

    Neurology. 2000;55(11 Suppl 4):S2-7; discussion S8-12. Review.PMID: 11147506 [PubMed - indexed for MEDLINE]Related articles

    16.

    Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO study.

    Przuntek H, Welzel D, Gerlach M, Blümner E, Danielczyk W, Kaiser HJ, Kraus PH, Letzel H, Riederer P, Uberla K.

    J Neural Transm. 1996;103(6):699-715.PMID: 8836932 [PubMed - indexed for MEDLINE]Related articles

    17.

    Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. Parkinson's Disease Research Group in the United Kingdom.

    [No authors listed]

    BMJ. 1993 Aug 21;307(6902):469-72.PMID: 8400928 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Overview of present day treatment of Parkinson's disease.

    Yahr MD.

    J Neural Transm. 1978;43(3-4):227-38.PMID: 745015 [PubMed - indexed for MEDLINE]Related articles

    19.

    Levodopa and decarboxylase inhibitors: a review of their clinical pharmacology and use in the treatment of parkinsonism.

    Pinder RM, Brogden RN, Sawyer PR, Speight TM, Avery GS.

    Drugs. 1976;11(5):329-77. Review. No abstract available. PMID: 782834 [PubMed - indexed for MEDLINE]Related articles

    20.

    Dose-related levodopa-induced haemolytic anaemia.

    Linström FD, Liedén G, Enström MS.

    Ann Intern Med. 1977 Mar;86(3):298-300.PMID: 402877 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity